Restatement of Previously Issued Consolidated Financial Statements | NOTE 2 – Restatement of Previously Issued Consolidated Financial Statements On September 17, 2024, the Company determined that 5,000,000 options to purchase shares of our common stock granted to a consultant during the three months ended March 31, 2023 were omitted from its previously issued unaudited condensed consolidated financial statements for the quarterly periods ended March 31, 2023 through September 30, 2023, originally included in our Quarterly Reports on Form 10-Q for the periods ended March 31, 2023, June 30, 2023 and September 30, 2023 (collectively, the “Interim Periods” and together with the Annual Period, the “Affected Periods”). The Company evaluated the materiality of these misstatements both qualitatively and quantitatively in accordance with Staff Accounting Bulletin (“SAB”) No. 99, Materiality Considering the Effects of Prior Year Misstatements in Current Year Financial Statements A reconciliation from the amounts previously reported for the Affected Periods to the restated amounts in the Restated Consolidated Financial Statements is provided for the impacted financial statement line items below for: (i) the consolidated balance sheet as of June 30, 2024; (ii) the consolidated statement of operations for the six months ended June 30, 2023; (iii) the consolidated statement of changes in stockholders’ equity for the three and six ended June 30, 2023; and (iv) the consolidated statement of cash flows for the six months ended June 30, 2023. The amounts labeled “Restatement Adjustments” represent the effects of the Restatement Adjustments. The following table presents the effects of the Restatement Adjustments on the Company’s consolidated balance sheet as of June 30, 2024 and December 31, 2023: Restated financial information Balance as of June 30, 2024 As Previously Restatement As Stated Adjustments Restated Additional paid-in capital $ 35,142,231 $ 229,035 $ 35,371,266 Accumulated deficit $ (39,432,556 ) $ (229,035 ) $ (39,661,591 ) Balance as of December 31, 2023 As Previously Restatement As Stated Adjustments Restated Additional paid-in capital $ 35,142,231 $ 229,035 $ 35,371,266 Accumulated deficit $ (38,665,874 ) $ (229,035 ) $ (38,894,909 ) The following table presents the effects of the Restatement Adjustments on the Company’s consolidated statement of operations for the six months ended June 30, 2023: For the Six Months Ended June 30, 2023 As Previously Restatement As Stated Adjustments Restated Operating expenses: General and administrative expenses $ 2,123,026 $ 229,035 $ 2,352,061 Total operating expenses $ 2,130,370 $ 229,035 $ 2,359,405 Loss from operations $ (2,130,370 ) $ (229,035 ) $ (2,359,405 ) Loss before provision for income taxes $ (1,715,371 ) $ (229,035 ) $ (1,944,406 ) Net loss $ (1,715,371 ) $ (229,035 ) $ (1,944,406 ) Loss per common share - basic and diluted $ (0.00 ) $ – $ (0.00 ) Weighted average shares outstanding - basic and diluted 390,564,531 390,564,531 The following table presents the effects of the Restatement Adjustments on the Company’s consolidated statement of changes in stockholders’ equity for the three months ended June 30, 2024 and 2023: For the Three Months June 30, 2024 As Previously Restatement As Stated Adjustments Restated Additional Paid in Capital 35,142,231 229,035 35,371,266 Accumulated Deficit (39,432,556 ) (229,035 ) (39,661,591 ) For the Three Months June 30, 2023 As Previously Restatement As Stated Adjustments Restated Additional Paid in Capital 35,142,231 229,035 35,371,266 Accumulated Deficit (37,595,499 ) (229,035 ) (37,824,534 ) The following table presents the effects of the Restatement Adjustments on the Company’s consolidated statement of cash flows for the six months ended June 30, 2023: For the Six Months Ended June 30, 2023 As Previously Restatement As Stated Adjustments Restated Net loss $ (1,715,371 ) $ (229,035 ) $ (1,944,406 ) Stock-based compensation $ 1,236,487 $ 229,035 $ 1,465,522 Net cash provided by (used in) operating activities $ 400,994 $ – $ 400,994 |